Skip to main content

TGTX TG Therapeutics, Inc.

Healthcare

61.18 Close 10/30
Since 2024-12-02 +74.4%
Open
58.15
High
61.76
Low
58.00
Prev close
58.08
Volume
2.8M
Amplitude
6.47%
P/E
22.3
P/B
15.5
Revenue YoY (TTM)
+76.1%
52W 26.76 61.76

Is TG Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Good, Growth: Strong, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E 22.33 58th percentile Pricey
Price / book 15.5 95th percentile Expensive
Free-cash-flow yield (%) -0.01 48th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good ROE, TTM is Top, but FCF margin, TTM is Average.
ROE, TTM (%) 73.08 93th percentile Top
Operating margin, TTM (%) 17.05 68th percentile Good
FCF margin, TTM (%) -0.07 39th percentile Average
Quality Factor Investing: A US Quality Value Backtest
Growth Strong All 2 indicators are Top.
Revenue growth, TTM YoY (%) 76.08 90th percentile Top
Diluted EPS growth, TTM YoY (%) 638.35 95th percentile Top
Momentum Strong All 2 indicators are Top.
60-day return (%) 23.47 93th percentile Top
240-day return (%) 97.35 95th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 84,430,523 86th percentile Top
60-day annualized volatility (%) 37.17 43th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

TG Therapeutics, Inc. (TGTX) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From TG Therapeutics, Inc. to every stock like it

AI finds several complementary traits of TG Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like TG Therapeutics, Inc.

TG Therapeutics, Inc. (TGTX) peers and tracking

Watchlist

This page refreshes daily after the close. Add TG Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

TG Therapeutics, Inc. (TGTX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

19 historical occurrences (since 2017-03-07)

Average forward return after 52-week adjusted-price high

20-day: Win 55.6%, Sample 18, Median +1.59%, Excess +6.99%, Beat mkt rate 50%

60-day: Win 83.3%, Sample 18, Median +19.07%, Excess +14.84%, Beat mkt rate 77.8%

120-day: Win 70.6%, Sample 17, Median +34.48%, Excess +23.4%, Beat mkt rate 70.6%

120 days after: historical avg +32.18%

20-day +8.04%
60-day +19.75%
120-day +32.18%
20-day
60-day
120-day
Win
55.6%
83.3%
70.6%
Sample
18
18
17
Median
+1.59%
+19.07%
+34.48%
Excess
+6.99%
+14.84%
+23.4%
Beat mkt rate
50%
77.8%
70.6%

Over 17 occurrences, 120-day forward avg gained 32.18%, beat the market by 23.4 pts; win rate 70.6%.

Top-quintile 6-month momentum

Active · now 96.26%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
19 historical occurrences (since 2017-03-06)

Average forward return after Top-quintile 6-month momentum

20-day: Win 63.2%, Sample 19, Median +6.03%, Excess +7%, Beat mkt rate 57.9%

60-day: Win 63.2%, Sample 19, Median +15.26%, Excess +14.91%, Beat mkt rate 63.2%

120-day: Win 64.7%, Sample 17, Median +20.57%, Excess +36.66%, Beat mkt rate 64.7%

120 days after: historical avg +44.5%

20-day +8.35%
60-day +18.63%
120-day +44.5%
20-day
60-day
120-day
Win
63.2%
63.2%
64.7%
Sample
19
19
17
Median
+6.03%
+15.26%
+20.57%
Excess
+7%
+14.91%
+36.66%
Beat mkt rate
57.9%
63.2%
64.7%

Over 17 occurrences, 120-day forward avg gained 44.5%, beat the market by 36.66 pts; win rate 64.7%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 times historically; 60-day forward avg -11.46%, win rate 33.3%, beating the market by -12.56 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

14 times historically; 60-day forward avg +8.44%, win rate 38.5%, beating the market by +5 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.